IL197892A0 - Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto - Google Patents

Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto

Info

Publication number
IL197892A0
IL197892A0 IL197892A IL19789209A IL197892A0 IL 197892 A0 IL197892 A0 IL 197892A0 IL 197892 A IL197892 A IL 197892A IL 19789209 A IL19789209 A IL 19789209A IL 197892 A0 IL197892 A0 IL 197892A0
Authority
IL
Israel
Prior art keywords
sulfonyl
histamine
modulators
phenyl
treatment
Prior art date
Application number
IL197892A
Other languages
English (en)
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of IL197892A0 publication Critical patent/IL197892A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
IL197892A 2006-10-17 2009-04-05 Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto IL197892A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85261006P 2006-10-17 2006-10-17
US93435807P 2007-06-11 2007-06-11
PCT/US2007/022086 WO2008048609A1 (en) 2006-10-17 2007-10-16 Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto

Publications (1)

Publication Number Publication Date
IL197892A0 true IL197892A0 (en) 2009-12-24

Family

ID=39149258

Family Applications (1)

Application Number Title Priority Date Filing Date
IL197892A IL197892A0 (en) 2006-10-17 2009-04-05 Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto

Country Status (16)

Country Link
US (1) US20100240653A1 (OSRAM)
EP (1) EP2074086B1 (OSRAM)
JP (1) JP2010506918A (OSRAM)
KR (1) KR20090069333A (OSRAM)
AR (1) AR063226A1 (OSRAM)
AT (1) ATE512948T1 (OSRAM)
AU (1) AU2007313180A1 (OSRAM)
CA (1) CA2665204A1 (OSRAM)
CL (1) CL2007002977A1 (OSRAM)
EA (1) EA200970386A1 (OSRAM)
IL (1) IL197892A0 (OSRAM)
MX (1) MX2009004071A (OSRAM)
PA (1) PA8750901A1 (OSRAM)
PE (1) PE20081462A1 (OSRAM)
TW (1) TW200823204A (OSRAM)
WO (1) WO2008048609A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20060100T3 (en) 2003-07-22 2007-03-31 Arena Pharmaceuticals Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
TWI415845B (zh) * 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US20100292288A1 (en) * 2007-06-08 2010-11-18 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-[4`- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
EP2190844B3 (en) 2007-08-15 2013-07-17 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2009123714A2 (en) * 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
EP2282992A1 (en) * 2008-04-16 2011-02-16 Arena Pharmaceuticals, Inc. Processes useful for the synthesis of (r)-1-{2-ý4'-(3-methoxypropane-1-sulfonyl)-biphenyl-4-yl¨-ethyl}-2-methyl-pyrrolidine
TR201805216T4 (en) 2008-10-28 2018-06-21 Arena Pharm Inc COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
GB201005511D0 (en) 2010-03-31 2010-05-19 Takeda Pharmaceutical Compounds and their use
FR2974729B1 (fr) * 2011-05-02 2013-04-19 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP3889141A1 (en) * 2013-01-09 2021-10-06 Arena Pharmaceuticals, Inc. (r)-3-(4'-(2-(2-methylpyrrolidin-1-yl)ethyl)biphenyl-4-yl)propanoic acid as histamine h3 receptor modulators for the treatment of cognitive disorders
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2020092604A1 (en) * 2018-10-30 2020-05-07 Concert Pharmaceuticals, Inc. Deuterated pitolisant
EP4251148A1 (en) 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder
CN115160584B (zh) * 2022-07-06 2024-03-22 西北工业大学 一种基于阳离子-π与静电作用协同构筑异质孔超分子有机框架及制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352707A (en) * 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5217986A (en) * 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
US5500427A (en) * 1992-09-14 1996-03-19 Takeda Chemical Industries, Ltd. Cyclic compounds and their use
US5541217A (en) * 1995-05-17 1996-07-30 Ortho Pharmaceutical Corporation 4-arylcyclopenta[c]pyrrole analgesics
US5869479A (en) * 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
DE19937537A1 (de) * 1999-08-09 2001-03-08 Gruenenthal Gmbh Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate
US20040044029A1 (en) * 2002-08-14 2004-03-04 Dart Michael J. Azabicyclic compounds are central nervous system active agents
US7244852B2 (en) * 2003-02-27 2007-07-17 Abbott Laboratories Process for preparing 2-methylpyrrolidine and specific enantiomers thereof
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
MXPA06011167A (es) * 2004-04-01 2007-01-25 Eli Lilli And Company Agentes del receptor h3 de histamina, preparacion y usos terapeuticos.
US20050245543A1 (en) * 2004-04-30 2005-11-03 Pfizer Inc Histamine-3 receptor antagonists
US7145005B2 (en) * 2004-05-12 2006-12-05 Abbott Laboratories 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
AU2005280921B2 (en) * 2004-09-07 2011-05-19 Msd K.K. Carbamoyl-substituted spiro derivative
WO2006058649A1 (en) * 2004-12-03 2006-06-08 F. Hoffmann-La Roche Ag 3-substituted pyridine derivatives as h3 antagonists
CN101107227B (zh) * 2005-01-19 2010-09-22 霍夫曼-拉罗奇有限公司 5-氨基吲哚衍生物
US20060188960A1 (en) * 2005-02-18 2006-08-24 Waters Stephen M Chimeric histamine H3 receptor
PL1899334T3 (pl) * 2005-06-17 2009-04-30 Janssen Pharmaceutica Nv Związki naftyrydynowe
UA96424C2 (ru) * 2005-09-16 2011-11-10 Янссен Фармацевтика Н.В. Циклопропил амины как модуляторы н3 рецепторов гистамина
BRPI0619268A2 (pt) * 2005-11-30 2011-09-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal
KR20080080201A (ko) * 2005-12-21 2008-09-02 쉐링 코포레이션 히스타민 ｈ3 길항제로서 유용한 치환된 아닐린 유도체
MX2008011791A (es) * 2006-03-15 2008-09-25 Wyeth Corp Azaciclilaminas-n-sustituidas como antagonistas de histamina-3.
MX2008014743A (es) * 2006-05-19 2008-12-01 Wyeth Corp N-benzoil- y n-bencilpirrolidin-3-ilaminas como antagonistas de histamina-3.
AU2007256931B2 (en) * 2006-05-30 2013-01-24 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine H3 receptor
JP2009542673A (ja) * 2006-06-29 2009-12-03 アリーナ ファーマシューティカルズ， インコーポレイテッド ヒスタミンｈ３−受容体関連障害の治療に有用なヒスタミンｈ３−受容体モジュレータ
US7507736B2 (en) * 2007-02-07 2009-03-24 Hoffmann-La Roche Inc. Indol-2-yl-piperazin-1-yl-methanone derivatives
US7648979B2 (en) * 2007-02-07 2010-01-19 Hoffmann-La Roche Inc. 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives
US7557108B2 (en) * 2007-02-07 2009-07-07 Hoffmann-La Roche Inc. (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones
US7846930B2 (en) * 2007-05-18 2010-12-07 Janssen Pharmaceutica Nv Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators
KR20100020487A (ko) * 2007-05-24 2010-02-22 와이어쓰 엘엘씨 히스타민-3 길항제로서 아자시클릴벤즈아미드 유도체
TW200918062A (en) * 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
AP2010005202A0 (en) * 2007-09-12 2010-04-30 Wyeth Llc Isoquinolinyl and isoindolinyl derivatives as histamines-3 antagonists
WO2009067406A1 (en) * 2007-11-20 2009-05-28 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
US8236792B2 (en) * 2008-05-23 2012-08-07 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine H3 receptor
US20100130477A1 (en) * 2008-11-25 2010-05-27 Astrazeneca Ab Spirocyclobutyl Piperidine Derivatives

Also Published As

Publication number Publication date
WO2008048609A1 (en) 2008-04-24
KR20090069333A (ko) 2009-06-30
CA2665204A1 (en) 2008-04-24
AU2007313180A1 (en) 2008-04-24
EP2074086A1 (en) 2009-07-01
EA200970386A1 (ru) 2009-10-30
JP2010506918A (ja) 2010-03-04
PE20081462A1 (es) 2008-10-18
TW200823204A (en) 2008-06-01
PA8750901A1 (es) 2009-03-31
CL2007002977A1 (es) 2008-06-06
MX2009004071A (es) 2009-04-28
AR063226A1 (es) 2009-01-14
US20100240653A1 (en) 2010-09-23
EP2074086B1 (en) 2011-06-15
ATE512948T1 (de) 2011-07-15

Similar Documents

Publication Publication Date Title
IL197892A0 (en) Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
PT1881823E (pt) Composições e métodos para o tratamento de transtornos oculares
GB2423107B (en) Apparatus for the creation of outer surfaces for structures
ZA200900051B (en) Modulators of metabolism and the treatment of disorders related thereto
ZA200900055B (en) Modulators of metabolism and the treatment of disorders related thereto
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
AP3091A (en) Agents for preventing and treating disorders involving modulation of the RYR receptors
IL179508A0 (en) 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
ZA200901523B (en) Use of extracts for the treatment of viral disorders
IL193747A0 (en) New therapeutic combinations for the treatment of depression
AP2008004436A0 (en) Odcase inhibitors for the treatment of malaria
WO2009063492A9 (en) Novel agents for treatment of ailments and dysfunctions
EP2191835A4 (en) THERAPEUTIC AND PROPHYLACTIC AGENTS FOR ARTHRITIS
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
IL193697A0 (en) Methods for treating cognitive and other disorders
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
EP2211771A4 (en) Apparatus for the treatment of gallstones
GB2429461B (en) Treatment of hydrocarbons
ZA200902643B (en) Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
HK1132735A (en) Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
HK1122813A (en) Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
IL198479A0 (en) Methods for screening for therapeutic molecules and use of the molecules therefrom
GB0625234D0 (en) Treatment of Hydrocarbons